Research Article
Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
Table 2
Baseline disease activity of patients.
| | | Placebo () | AT naïve () | AT continuing () |
| | Organ involvement, n (%) | | | | | BILAG max | | | | | A | 0 (0.0%) | 0 (0.0%) | 1 (20.0%) | | B | 5 (35.7%) | 4 (26.7%) | 0 (0.0%) | | C | 2 (14.3%) | 3 (20.0%) | 1 (20.0%) | | D | 7 (50.0%) | 8 (53.3%) | 3 (60.0%) | | E | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | | (%) C or above | | | | | Constitutional | 4 (28.6%) | 0 (0.0%) | 1 (20.0%) | | Mucocutaneous | 5 (35.7%) | 3 (20.0%) | 1 (20.0%) | | Neurological | 2 (14.3%) | 3 (20.0%) | 1 (20.0%) | | Musculoskeletal | 6 (42.9%) | 5 (33.3%) | 2 (40.0%) | | Cardiorespiratory | 1 (7.1%) | 1 (6.7%) | 0 (0.0%) | | Gastrointestinal | 1 (7.1%) | 0 (0.0%) | 0 (0.0%) | | Ophthalmic | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | | Renal | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | | Haematological | 1 (7.1%) | 0 (0.0%) | 0 (0.0%) | | SLEDAI, median (IQR) | 2.00 (0.00 to 6.50) | 4.00 (0.00 to 6.00) | 2.00# | | SLICC total, median (IQR) | 1.50 (0.75 to 3.00) | 2.00 (0.00 to 3.00) | 1.00# | | (%) > 0 | | | | | Ocular | 2 (14.3%) | 2 (13.3%) | 0 (0.0) | | Neurological | 7 (50.0%) | 8 (53.3%) | 2 (40.0%) | | Renal | 1 (7.1%) | 0 (0.0%) | 1 (20.0%) | | Pulmonary | 2 (14.3%) | 3 (20.0%) | 0 (0.0%) | | Cardiovascular | 2 (14.3%) | 1 (6.7%) | 1 (20.0%) | | Peripheral vascular | 2 (14.3%) | 1 (6.7%) | 0 (0.0%) | | Gastrointestinal | 0 (0.0%) | 0 (0.0%) | 1 (20.0%) | | Musculoskeletal | 4 (28.5%) | 4 (26.7%) | 2 (40.0%) | | Skin | 0 (0.0%) | 1 (6.7%) | 0 (0.0%) | | Gonadal failure | 2 (14.3%) | 1 (6.7%) | 0 (0.0%) | | Diabetes mellitus | 0 (0.0%) | 0 (0.0%) | 1 (20.0%) | | Malignancy | 1 (7.1%) | 1 (6.7%) | 0 (0.0%) |
|
|
AT: atorvastatin; BILAG: British Isles Lupus Assessment Group; SLEDAI: systemic lupus erythematosus disease activity index; SLICC: Systemic Lupus International Collaborative Clinics damage index; IQR: interquartile range. #IQR not calculated due to small sample size.
|
